SITE002-0171

SITE002 (USA) › SITE002-0171

SITE002-0171

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2026-03-26

enrolled

AEs

2

Serious

1

Dropout signal

–

Adverse events

2

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-08 (study day 160); relationship: NOT RELATED

mild assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 65); relationship: NOT RELATED; serious criteria: hospitalization

severe serious assessed

Data queries

0

No data queries. Open queries would appear here for this patient.